Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
LOXL2 encodes a member of the lysyl oxidase gene family. Additionally we are shipping Lysyl Oxidase-Like 2 Kits (19) and Lysyl Oxidase-Like 2 Proteins (18) and many more products for this protein.
Showing 10 out of 96 products:
Human Monoclonal LOXL2 Primary Antibody for ELISA, WB - ABIN396576
Rodriguez, Vaysberg, Mikels, McCauley, Velayo, Garcia, Smith: Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor. in The Journal of biological chemistry 2010
Show all 5 references for ABIN396576
Human Polyclonal LOXL2 Primary Antibody for EIA, WB - ABIN953202
Rückert, Joensson, Saeger, Grützmann, Pilarsky: Functional analysis of LOXL2 in pancreatic carcinoma. in International journal of colorectal disease 2010
Show all 4 references for ABIN953202
Human Monoclonal LOXL2 Primary Antibody for ELISA, WB - ABIN561690
Fujimoto, Tajima: Reciprocal regulation of LOX and LOXL2 expression during cell adhesion and terminal differentiation in epidermal keratinocytes. in Journal of dermatological science 2009
Show all 3 references for ABIN561690
Human Polyclonal LOXL2 Primary Antibody for ELISA, WB - ABIN561689
Ghiggeri, Gigante, Di Donato et al.: Constitutional Nephrin Deficiency in Conditionally Immortalized Human Podocytes Induced Epithelial-Mesenchymal Transition, Supported by β-Catenin/NF-kappa B Activation: A Consequence of Cell Junction ... in International journal of nephrology 2014
Dmloxl-1 and Dmloxl-2 are differentially expressed; active DmLOXL-1 influences gene expression and development
Loss of tumor-suppressive miR29s enhanced cancer cell invasion in lung SCC (show CYP11A1 Antibodies) through direct regulation of oncogenic LOXL2.
LOXL2 promotes tumor progression.
We identified LOXL2 to be associated with the outcome of colon cancer patients. Furthermore, it can be used to stratify patients at stages II and III for further therapeutic decisions.
Data suggest that restoration of MIRN29 (microRNA 29) synthesis silences expression of LOXL2 (lysyl oxidase-like 2) and inhibits cell proliferation, migration, and invasiveness of renal cell carcinoma (show MOK Antibodies) cells.
Lysine oxidation of the transcription factor TAF10 (show TAF10 Antibodies) by LOXL2 is a controlled protein modification and demonstrates a role for protein oxidation in regulating pluripotency genes.
Results show that LOXL2 is highly expressed and involved in clear cell renal cell carcinoma (show MOK Antibodies) progression by regulating the levels of integrins a5 and b1.
identified novel alternative splicing isoform, LOXL2 Deltae13; data suggest it modulates effects of cancer cell migration and invasion through a different mechanism from full-length LOXL2 and may play an important role in tumor carcinogenesis and progression
The structure and functions of human lysyl oxidase-like 2 (LOXL2) are reviewed. [review]
LOXL2 is a direct repressor of NOTCH1 (show NOTCH1 Antibodies).There is an exclusive expression pattern between LOXL2 and members of the canonical NOTCH1 (show NOTCH1 Antibodies) pathway in human head and neck squamous cell carcinoma.
Data indicate potential roles of LOXL2 (lysyl oxidase-like 2) splice variants with large scale data.
LOX (show LOX Antibodies) and LOXL2 (show LOXL3 Antibodies) may play an important role in the pathogenesis of AMD (show AMD1 Antibodies). Targeting LOXL2 (show LOXL3 Antibodies) could have a broader efficacy than targeting LOX (show LOX Antibodies), by reducing angiogenesis and inflammation, as well as fibrosis.
Loss and gain of function analyses combined with in vivo studies in syngeneic breast cancer models demonstrate the participation of LOXL2 (show LOXL3 Antibodies) and E47 (show TCF3 Antibodies) in tumor growth and their requirement for lung metastasis.
Findings reveal new insight into the mechanisms of fibroblast activation, a novel function of LOXL2 (show LOXL3 Antibodies), and further highlight the importance of generating LOXL2 (show LOXL3 Antibodies)-targeted therapies for the prevention of tumor progression and metastasis.
The Snail1 (show SNAI1 Antibodies) transcription factor represses mouse pericentromeric transcription, acting through the H3K4 deaminase LOXL2 (show LOXL3 Antibodies).
The enzymatic activity of lysyl oxidas-like-2 (LOXL2 (show LOXL3 Antibodies)) is not required for LOXL2 (show LOXL3 Antibodies)-induced inhibition of keratinocyte differentiation.
This study provides the first evidence for the role of LOXL2 (show LOXL3 Antibodies) in regulating angiogenesis through collagen IV (show COL4 Antibodies) scaffolding.
LOXL2 (show LOXL3 Antibodies) promotes chondrocyte differentiation by mechanisms that are likely to include roles as both a regulator and an effector of chondrocyte differentiation
The efficacy and safety of LOXL2 (show LOXL3 Antibodies)-specific monoclonal antibody represents a new therapeutic approach with broad applicability in oncologic and fibrotic diseases.
LoxL2 (show LOXL3 Antibodies) is not expressed in MC3T3-E1 cells.
This gene encodes a member of the lysyl oxidase gene family. The prototypic member of the family is essential to the biogenesis of connective tissue, encoding an extracellular copper-dependent amine oxidase that catalyses the first step in the formation of crosslinks in collagens and elastin. A highly conserved amino acid sequence at the C-terminus end appears to be sufficient for amine oxidase activity, suggesting that each family member may retain this function. The N-terminus is poorly conserved and may impart additional roles in developmental regulation, senescence, tumor suppression, cell growth control, and chemotaxis to each member of the family.
, lysyl oxidase-like 2
, Lysyl oxidase-like protein 2
, lysyl oxidase homolog 2
, lysyl oxidase homolog 2-like
, lysyl oxidase related 2
, lysyl oxidase-like protein 2
, lysyl oxidase-related protein 2
, lysyl oxidase-related protein WS9-14
, Lysyl oxidase homolog 2